Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Akif S. Yavuz"'
Autor:
Hermann J. Girschick, Amrie C. Grammer, Peter E. Lipsky, Nancy S. Longo, Sule Yavuz, Akif S Yavuz, Nancy L. Monson
Publikováno v:
Molecular Immunology. 39:485-493
Mutations within the 5'-non-coding region of the bcl-6 gene can occur in lymphomas that originate from germinal centers (GCs), as well as in normal memory and GC B cells. Mutations in the p53 gene occur in 50% of human cancers. Since both bcl-6 and p
Publikováno v:
The Journal of allergy and clinical immunology. 115(6)
Background Mast cells and basophils share similar morphologic and functional properties; however, it is not known whether they are derived from a bilineage (basophil/mast cell)–restricted progenitor. Objective To assess whether basophils and mast c
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
Publikováno v:
Blood. 103(8)
Mutational analysis of the c-kit gene in a patient with a previously undescribed variant of mast cell disease revealed a germline mutation, Phe522Cys, within the transmembrane portion of the Kit receptor protein. Transfection experiments revealed tha
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 169(7)
To determine the possible role of polymerase η (pol η) in somatic hypermutation of B cells, a mutational analysis of 24 nonproductive rearrangements from a patient with xeroderma pigmentosum variant with a defect in pol η was conducted. Although t
Autor:
Guray Saydam, Ibrahim C. Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan M. Ayyildiz, Diyar Z. Akkaynak, Ilkiz M. Dag, Osman Ilhan
Publikováno v:
Blood. 122:2742-2742
Introduction Nilotinib, a more potent and selective drug than imatinib, was approved by the FDA and EMA initially for the treatment of chronic and accelerated phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) patients re